IRVINE, Calif., Nov. 8, 2011 /PRNewswire/ --Masimo (NASDAQ: MASI) announced today that it has received the American Association of Respiratory Care's (AARC) prestigious Zenith Award for the fourth straight year. Honored at the 57th Annual International Respiratory Congressthe largest gathering of respiratory care clinicians in the worldthe AARC's Zenith Award represents Masimo's unwavering commitment, dedication, and industry leadership in providing best-in-breed, innovative patient care solutions.
AARC Executive Director and CEO, Sam Giordano, stated," I congratulate Masimo for earning another Zenith Award this year. Companies receiving this prestigious award are chosen based on quality of products, truth in advertising, service, responsiveness, accessibility of sales staff, and support of the respiratory care profession. This year marks the fourth consecutive year that Masimo was voted to receive a Zenith by members of the American Association for Respiratory Care."
The leading national and international professional association for respiratory care, AARC encourages and promotes professional excellence, advances the science and practice of respiratory care, and serves as an advocate for patients and their families, the public, the profession and the respiratory care therapist. As the AARC's top industry honor for quality and service excellence, more than 400 companies were eligible for one of five Zenith Award honors. Award winners are chosen by the association's membershipmore than 52,000 respiratory care professionals.
Joe Kiani, Chairman and CEO of Masimo, stated, "Respiratory professionals are a crucial component of the patient care team and their expertise is fundamental to patient recovery. We are proud of our longstanding commitment to the respiratory profession and are honored by the appreciation of so many AARC members who have once again recognized us with the Zenith Award for the superior quality and performance of our products and the service, commitment, and integrity excellence of our Team."
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient carehelping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow SET® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOC), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). In 2008, Masimo introduced Patient SafetyNet, a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events. In 2009, Masimo introduced rainbow Acoustic Monitoring, the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa). Masimo's rainbow SET technology platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options. In 2010, Masimo acquired SEDLine®, a pioneer in the development of innovative brain function monitoring technology and devices. Masimo SET and Masimo rainbow SET technologies can be also found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world. Founded in 1989, Masimo has the mission of "Improving Patient Outcome and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications®." Additional information about Masimo and its products may be found at www.masimo.com. *To see a summary of all known clinical studies and abstracts on Masimo technologies, please visit: http://www.masimo.com/cpub/clinicals.htm.
Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57,Rad-8, Rad-5,Pulse CO-Oximetry, Pulse CO-Oximeter, Adaptive Threshold Alarm, and SEDLine are trademarks or registered trademarks of Masimo Corporation. The use of the trademarks Patient SafetyNet and PSN is under license from University HealthSystem Consortium.
SOURCE Masimo Corporation